New Delhi, Apr 2: Indian biotechnology and biopharmaceutical company Biological E ‘s Corbevax, the Covid vaccine after getting a nod from the centre is currently being used in for children aged 12-14 years.
The vax was approved based on its interim safety and immunogenicity data, the Union Ministry of Health and Family Welfare told the Lok Sabha in a written reply Friday.
Immunogenicity is defined as the ability of any agent that has been introduced into the human body to provoke an immune response.
The ministry was responding to a question raised by Trinamool Congress MP Dipak Adhikari on the availability of safety and efficacy data for the vaccine, and whether it had been peer-reviewed.
“Based on the interim safety & immunogenicity data of Phase II/III clinical trial conducted in subjects of ≥ 5 to <18 (greater than five and less than 18) years age group, Central Drugs Standard Control Organisation (CDSCO), the national regulator, in consultation with subject expert committee (SEC) has granted permission to manufacture SARS-CoV-2 vaccine [CORBEVAX] of M/s Biological E Limited for restricted use in emergency situation in ≥ 12 to <18 (over 12 and less than 18) years age group,” Minister of State (MoS) Dr Bharati Pravin Pawar told the Lower House.
